Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

What’s your thoughts on the path forward.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Stockfun1 Member Profile
 
Followed By 13
Posts 522
Boards Moderated 0
Alias Born 07/23/17
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2020 10:43:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/30/2020 6:59:54 AM
Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome... GlobeNewswire Inc. - 6/30/2020 6:45:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2020 5:43:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2020 5:41:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2020 5:39:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2020 5:37:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2020 5:34:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2020 5:31:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2020 4:11:14 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/2/2020 4:14:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2020 7:32:30 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/27/2020 7:11:49 AM
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Auti... GlobeNewswire Inc. - 5/27/2020 6:45:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 7:16:03 AM
Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fra... GlobeNewswire Inc. - 5/26/2020 6:52:10 AM
Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental ... GlobeNewswire Inc. - 5/26/2020 6:50:10 AM
Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire Inc. - 5/22/2020 7:30:10 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/21/2020 8:01:04 AM
Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic GlobeNewswire Inc. - 5/21/2020 8:00:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/11/2020 2:44:27 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/11/2020 8:02:24 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/11/2020 7:02:05 AM
Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights GlobeNewswire Inc. - 5/11/2020 6:50:10 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/23/2020 9:04:41 AM
Stockfun1   Wednesday, 07/01/20 01:10:11 AM
Re: dhbuzz post# 2484
Post # of 2526 
What’s your thoughts on the path forward. IMHO, because this is still passing the MDA with FDA and still will be used heavily by physicians for FX. Even those without 90% methylation. Plus...because there are 3 more indications ( particularly ASD, this is still a winner. Market over reaction has made this a very good buy ( if anyone has powder to spend now) . Curious about your thoughts.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist